Phase I Efficacy & Safety Study of Serclutamab Talirine, an EGFR Targeting Antibody Drug Conjugate, in Subjects with Recurrent Glioblastoma (GBM)

Time: 12:30 pm
day: day 2 track 3


• Review of targeting EGFR with antibody drug conjugates in solid tumors • Examine the efficacy and safety of Serclutamab Talirine in subjects with recurrent glioblastoma • Discuss conclusions and future directions